This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news
Addressing Unmet Needs in Pulmonary Arterial Hypertension - MedPage Today
Addressing Unmet Needs in Pulmonary Arterial Hypertension MedPage Today Pulmonary arterial hypertension (PAH) remains a complex disease with many clinical challenges for physicians, including early recognition, accurate diagnosis, and delayed initiation of PAH-specific pharmacotherapy. Despite treatment advances, mortality ...
Assessment of Ambrisentan in Pulmonary Arterial Hypertension - The Cardiology Advisor
Assessment of Ambrisentan in Pulmonary Arterial Hypertension The Cardiology Advisor Ambrisentan (Volibris®; GlaxoSmithKline) is safe, tolerable, and possibly effective for improving hemodynamics in patients with pulmonary arterial hypertension (PAH), according to an interim report on a postmarketing surveillance study published in ...
Eiger BioPharmaceuticals Discontinues Development of Ubenimex in PAH After Disappointing Results - Lung Disease News
Global Cardiovascular Disease Drugs Market 2017-2023 - Expiries ... - Business Wire (press release)
Global Cardiovascular Disease Drugs Market 2017-2023 - Expiries ... Business Wire (press release) Global Cardiovascular Disease Drugs Market to 2023 provides an introduction to cardiovascular disease (CVD), including disease symptoms, diagnosis, etiology, pathophysiology, comorbidities and complications, epidemiology, prognosis and treatment. CVD ...
What our clients and candidates are saying about us: I enjoyed visiting your site very much. You and your staff at SHS are doing an impressive job with this site. Your pride in what you do is very evident. - David
The #1 Resource for professionals in the Pharmaceutical Advertising, Medical Communications, Healthcare Public Relations, Pharmaceutical Industry, and Biotechnology fields since 1988.